GAMMA Investing LLC raised its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 36,430.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,151 shares of the company's stock after purchasing an additional 13,115 shares during the period. GAMMA Investing LLC's holdings in Tarsus Pharmaceuticals were worth $676,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Crowley Wealth Management Inc. bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at about $25,000. GF Fund Management CO. LTD. bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at $44,000. Quarry LP acquired a new position in Tarsus Pharmaceuticals during the fourth quarter worth $166,000. HighTower Advisors LLC bought a new position in shares of Tarsus Pharmaceuticals in the 4th quarter valued at approximately $207,000. Finally, Summit Investment Advisors Inc. lifted its stake in shares of Tarsus Pharmaceuticals by 6.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock worth $213,000 after buying an additional 244 shares during the last quarter. Institutional investors own 90.01% of the company's stock.
Tarsus Pharmaceuticals Stock Up 4.2%
Tarsus Pharmaceuticals stock traded up $1.65 during midday trading on Thursday, reaching $41.07. The stock had a trading volume of 783,226 shares, compared to its average volume of 698,959. Tarsus Pharmaceuticals, Inc. has a 12 month low of $20.08 and a 12 month high of $57.28. The company has a fifty day moving average price of $45.27 and a two-hundred day moving average price of $48.40. The company has a current ratio of 5.57, a quick ratio of 5.54 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $1.73 billion, a P/E ratio of -15.04 and a beta of 0.83.
Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. The business had revenue of $78.34 million during the quarter, compared to analyst estimates of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 39.72% and a negative net margin of 44.91%. As a group, equities analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.
Insider Transactions at Tarsus Pharmaceuticals
In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 6,000 shares of the company's stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $50.00, for a total transaction of $300,000.00. Following the completion of the transaction, the chief executive officer now owns 824,106 shares of the company's stock, valued at $41,205,300. This represents a 0.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 8.97% of the company's stock.
Analyst Ratings Changes
A number of brokerages recently commented on TARS. HC Wainwright upgraded Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 target price for the company in a research note on Tuesday, May 27th. Jefferies Financial Group upped their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. Barclays cut their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Oppenheimer assumed coverage on Tarsus Pharmaceuticals in a research report on Monday, June 2nd. They set an "outperform" rating and a $75.00 price target for the company. Finally, The Goldman Sachs Group raised their price objective on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research report on Monday, May 5th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Tarsus Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $66.67.
Read Our Latest Research Report on Tarsus Pharmaceuticals
About Tarsus Pharmaceuticals
(
Free Report)
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Read More
Before you consider Tarsus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.
While Tarsus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
